Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2017

View Archived Issues

Selecta initiates phase I trial of nicotine vaccine candidate SELA-070

Ono Pharmaceutical updates key developments of fourth quarter of fiscal 2016

Seikagaku and Ono enter codevelopment and marketing collaboration on SI-613

ALLSTAR phase II trial of CAP-1002 unlikely to achieve primary efficacy endpoint

SB-415286 provides small molecule inhibition of PD-1 transcription

AAV9-CMV-TIPE2, a novel gene therapy for Duchenne muscular dystrophy

Ardelyx's phase III T3MPO-1 study of tenapanor meets primary endpoint

FDA grants fast track designation to Biohaven's trigriluzole for spinocerebellar ataxia

Esteve presents sigma 1 receptor ligands

French ANSM requests temporary suspension of masitinib trials in France

Hua Medicine patents metabotropic glutamate mGlu5 receptor antagonists

Trillium Therapeutics identifies novel fluorinated heterocycle derivatives

Boehringer Ingelheim discovers plasma kallikrein inhibitors

Pacira studies DepoTXA to reduce bleeding after total knee arthroplasty

Larotrectinib receives U.S. orphan designation for solid tumors with NTRK-fusion proteins

Daiichi Sankyo presents key milestones of fourth quarter of fiscal 2016

Shionogi & Co. divulges MGAT2 inhibitors

Polyclonal antibody preparation BT-086 can reduce severe community-acquired pneumonia mortality

Alunbrig available to order in U.S.

AbbVie reports pooled phase III outcomes data on ibrutinib in CLL/SLL

Galenica Ltd. shareholders approve change of name to Vifor Pharma Ltd.

Eli Lilly presents positive data from phase III studies of galcanezumab

SymBio suspends enrollment in phase III trial of SyB P-1501

pCCLChim-p47 gene therapy for autosomal-recessive chronic granulomatous disease shows promise

Phase Ib study shows potential of NGM-282 to treat constipation

Sumitomo Dainippon Pharma reviews developments of fourth quarter of fiscal 2016

Novartis' KAF-156 granted FDA orphan drug designation for malaria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...